SanFrancisco

After reading your post I was compelled to revisit "Resverlogix presents new data on RVX-208 orally active BET inhibitor at ESC Congress 2015. Not being a scientist, I am reticent to comment on the technical aspects of the actions of RVX-208, however these statements in the report yesterday are most intriguing:

Results showed significan decreases ranging from 7-12% vs. baseline in complement(i.e. complement factor 3) and coagulation components

The actions of RVX-208 lowered atherogenesis by downregulating (8 of 11) pro-atherogenic genes but in contrast, upregulated (5 of 7) anti-atherogenic genes that control monocyte recruitment, migration and activation, macrophage function, inflammatory signaling and plaque stability. Together, the new data from both primary human hepatocytes and whole blood suggest an overall anti-atherosclerotic benefit of RVX-208 that extends beyond its ApoA-I/HDL enhancing effects.

I initially found RVX after my second open heart surgery while looking for the holy grail. The promise of a drug that could clean my pipes really caught my attention. It seems to me that the statements in the aforementioned article about RVX's positive effects on blood and blood plasma seem to open up many more opportunities for RVX-208 and have really got my mind wandering. I may be way off base but could this be a replacement for Coumadin?

Chicagoest